Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Adds TSQ Quantum Tools to BRIMS Program as Goals Move Downstream

NEW YORK (GenomeWeb News) — Thermo Fisher Scientific said today it has expanded its Biomarker Research Initiative in Mass Spectrometry program to include new technology and programs that involve clinical validation and clinical application assays.
The BRIMS program, begun in 2004 with Massachusetts General Hospital, initially focused on discovering protein biomarkers, particularly those related to cardiovascular disease. It was intended to use Thermo’s LTQ FT and LTQ Orbitrap and other tools with Mass General’s bank of plasma samples.
BRIMS will now use Thermo’s TSQ Quantum triple-quadrupole platform and its TurboFlow sample-prep technology to develop assays for peptides and protein-biomarker quantitation.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.